Skip to content
Log in

Association of BDNF Val66Met polymorphism with clinical severity, cognitive function, and treatment response in schizophrenia

Juwita Saragih Irwan Saputra Marty Mawarpury E. M. Rahayuningsih
Jul 2026 · Narra X · Vol 4, pp. e300 · 0 citations · 42 references

TL;DR

BDNF Val66Met polymorphism was significantly associated with clinical symptom severity, cognitive function, and treatment-related improvement among Acehnese individuals with schizophrenia, and the Val/Val genotype was associated with a more favorable clinical and cognitive profile and stronger early clinical and cognitive response.

Abstract

The brain-derived neurotrophic factor gene (BDNF) Val66Met polymorphism has been implicated in neuroplasticity, cognitive performance, and variability in antipsychotic treatment response. However, evidence from Indonesian populations, particularly among individuals with schizophrenia from Aceh, remains limited. The aim of this study was to assess the association of BDNF Val66Met polymorphism with clinical symptom severity and cognitive function and to determine its association with clinical and cognitive outcomes after antipsychotic treatment. A prospective cohort study was conducted among Acehnese individuals with schizophrenia. Genotyping was performed using polymerase chain reaction–restriction fragment length polymorphism. Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive function was assessed using the Montreal Cognitive Assessment–Indonesian version (MoCA-INA) at Day 0, Day 14, and Day 42 post-therapy. Genotype–outcome associations were examined using genotype comparisons and genetic models. A total of 207 individuals with schizophrenia were analyzed. The Val/Met genotype was the most frequent genotype (52.2%), followed by Val/Val (28.0%) and Met/Met (19.8%). Baseline PANSS total score was significantly different across all genetic models, with the lowest symptom severity observed in the Val/Val group. In the dominant model, Met-allele carriers had higher PANSS total scores than Val/Val individuals (p<0.001). Baseline cognitive function also differed significantly, with Met-allele carriers showing lower MoCA-INA scores than Val/Val individuals (p<0.001). Clinical symptom improvement was consistently greater in Val/Val individuals, whereas Met-allele carriage was associated with smaller PANSS reductions at Day 14 and Day 42. For cognitive outcomes, Val/Val participants showed the greatest early improvement, while Met-allele carriers demonstrated slower initial recovery followed by later gains, resulting in more comparable cognitive improvement by Day 42 in some models. In conclusion, BDNF Val66Met polymorphism was significantly associated with clinical symptom severity, cognitive function, and treatment-related improvement among Acehnese individuals with schizophrenia. The Val/Val genotype was associated with a more favorable clinical and cognitive profile and stronger early clinical and cognitive response. These findings support the potential relevance of BDNF Val66Met as a population-specific biomarker for clinical stratification in schizophrenia, although further studies with longer follow-up and biological validation are warranted.

DOI Semantic Scholar
View source

Similar papers

Jul 2026

Relationship between BDNF rs6265 (VAL66MET) polymorphism and serum BDNF LEVELS in anxiety disorders

It is demonstrated that decreased serum BDNF levels are associated with the presence and symptom severity of anxiety disorders, and the Val66Met polymorphism does not appear to be a primary determinant of serum BDNF levels in this population, suggesting that other genetic or environmental factors may be involved.

Dicle Yilmaz Uyanik, Merve Şahin Can, O. Baykan et al. · 0 citations
Open access Aug 2026

Association between baseline cognition and clinical response in first-episode schizophrenia

This study aimed to investigate the association between baseline cognitive performance and the clinical response to antipsychotics in first-episode schizophrenia (FES) patients. This study examined 769 patients from a multi-center research cohort. Neurocognition was measured using the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia at baseline. Clinical response was defined as ≥ 50% reduction in PANSS total score from baseline to week 8. Pearson correlation analysis was performed for preliminary exploratory assessment. Multivariable logistic regression models (response: yes/no) were fitted with each cognitive domain as dependent variable, adjusted confounding factors. To test effect modification, we added interaction terms: (i) cognition × antipsychotic type and (ii) cognition × baseline illness severity. For domains with significant interactions ( P  < 0.05), stratified analyses were performed within each drug group and severity stratum. Logistic regression analysis demonstrated that all baseline neurocognitive domains were significantly associated with clinical response (All P  < 0.05). Significant interactions between neurocognitive performance and antipsychotics were observed across all domains except Working Memory and Reasoning/problem solving. Similarly, significant interactions between neurocognition and baseline illness severity were found for all domains except Visual and Verbal learning. Further stratified analyses revealed that baseline cognitive performance was associated to clinical response to amisulpride and risperidone. Additionally, significant associations between neurocognition and clinical response were consistently observed in patients with moderate-to-severe illness severity across all domains, with the exception of Visual and Verbal Learning. The association between baseline cognitive performance and treatment response is contingent on medication regimen and baseline illness severity. The study was registered on ClinicalTrials.gov (NCT03451734) with a registration date of January 23, 2018.

Yuanyuan Zhu, Ye Yang, R. Wu et al. · 0 citations
Review Open access Jul 2026

The prognostic potential of circulating BDNF levels and its polymorphisms in age-related cognitive impairment and neurodegeneration

Brain-derived neurotrophic factor (BDNF) is essential for neuronal survival, synaptic plasticity, and cognitive function. Age-related decline in BDNF signaling has been implicated in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and mild cognitive impairment. However, the prognostic value of circulating BDNF and its genetic variants remains controversial due to inconsistent findings across studies. This review synthesizes current evidence on peripheral BDNF levels and the Val66Met polymorphism as potential biomarkers of age-related cognitive decline and neurodegeneration. We critically analyze biological mechanisms linking BDNF to neurodegeneration, including its interaction with amyloid-beta and tau pathology. We further examine factors underlying discrepant results: demographic characteristics, comorbidities, lifestyle factors, pharmacological interventions, and methodological variability. Despite these challenges, BDNF remains a promising diagnostic factor. Nevertheless, standardizing preanalytical protocols and accounting for patient heterogeneity are essential to unlock its diagnostic potential.

Tatiana V. Tulupova, M. Vedunova, E. Mitroshina · 0 citations